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Abstract
Background: To date, detailed analyses of walking patterns using accelerometers during the 6-min walk test (6MWT) have
not been performed in patients with chronic obstructive pulmonary disease (COPD). Therefore, it remains unclear whether
and to what extent COPD patients have an altered walking pattern during the 6MWT compared to healthy elderly subjects.
Methodology/Principal Findings: 79 COPD patients and 24 healthy elderly subjects performed the 6MWT wearing an
accelerometer attached to the trunk. The accelerometer features (walking intensity, cadence, and walking variability) and
subject characteristics were assessed and compared between groups. Moreover, associations were sought with 6-min walk
distance (6MWD) using multiple ordinary least squares (OLS) regression models. COPD patients walked with a significantly
lower walking intensity, lower cadence and increased walking variability compared to healthy subjects. Walking intensity
and height were the only two significant determinants of 6MWD in healthy subjects, explaining 85% of the variance in
6MWD. In COPD patients also age, cadence, walking variability measures and their interactions were included were
significant determinants of 6MWD (total variance in 6MWD explained: 88%).
Conclusions/Significance: COPD patients have an altered walking pattern during 6MWT compared to healthy subjects.
These differences in walking pattern partially explain the lower 6MWD in patients with COPD.
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Introduction
The 6-minute walk test (6MWT) is commonly used to assess
functional exercise performance in patients with chronic obstruc-
tive pulmonary disease (COPD) [1]. It is a practical, relatively
simple test which has gained importance in evaluating the
functional status of patients with COPD [2]. Moreover, a poor
6-minute walk distance (6MWD, ,350 meters) has prognostic
value in patients with COPD [2].
The 6MWD cannot be confidently predicted from conventional
descriptors of COPD, such as the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) stage or the Medical Research
Council (MRC) scale [3]. Therefore, it is necessary to assess
functional exercise performance in daily clinical practice in
patients with COPD.
Walking patterns are generally influenced by the trade-off
between the requirements to minimize energetic costs and to
maintain stability [4]. Indeed, walking is particularly unstable in
the medio-lateral direction (Figure 1). To compensate for balance
disturbances during walking, active adjustment of the step width
(largely due to through lateral foot placement) is necessary
resulting in variability in walking pattern [4]. Then again, to
reduce energetic costs of walking, variability in walking pattern
needs to be minimized [5]. In COPD patients, different clinical
characteristics, such as decreased lower-limb muscle function [6]
and a disturbed balance [7], may compromise the ability to
balance the energetic and stability requirements posed by walking.
Hence, the walking pattern during 6MWT most probably is
different between patients with COPD and healthy elderly subjects
[8].
Detailed analyses of walking patterns during the 6MWT have
not yet been performed in patients with COPD. Yentes et al.
recently reported gross walking abnormalities in patients with
COPD, such as the presence of a limp or shuffle [9]. These
authors used qualitative assessment of gait abnormalities and did
not asses the spatiotemporal aspects of walking abnormalities. The
latter would enable a direct comparison of walking pattern
between patients with COPD and healthy elderly subjects; and an
examination of the association between walking pattern, 6MWD
and clinical characteristics, like weight, height, the degree of
airflow limitation and exercise-induced symptoms of dyspnea and
fatigue.
Features derived from tri-axial accelerometers attached to the
lower back can be used to measure walking variability. Acceler-
ometers may also allow monitoring walking abnormalities in
patients with COPD, as was done before in patients with chronic
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performance in a home-based setting in the context of telemed-
icine seems possible when close associations between accelerom-
eter features and walking distance are found. Therefore, the aim of
this study was to determine walking patterns during the 6MWT of
COPD patients and healthy elderly subjects. A priori, the authors
hypothesized that patients with COPD have a different walking
pattern during 6MWT compared to healthy elderly subjects,
which is related to the reduced 6MWD in COPD independent of
the degree of airflow limitation.
Methods
Participants
Patients were recruited prospectively during a three-day pre-
rehabilitation assessment period at CIRO+, a centre of expertise
for chronic organ failure in Horn, the Netherlands [11]. Exclusion
criteria were exacerbation-related hospitalization within 4 weeks
prior to assessment and the use of a rollator, which is expected to
affect the walking pattern [12]. Moreover, patients were excluded
from analyses if they were not able to walk at least one 6MWT
continuously for six minutes. In all cases non-continuous walks
resulted in a worse 6MWD. This is necessary to obtain reliable
measures of walking variability [13]. Moreover walking variability
cannot be measured over non-walking time.
In total, 93 patients enrolled, of which 14 (15%) stopped during
both 6MWT. Therefore, 79 COPD patients were included in the
analyses (n=8 GOLD 1, n=36 GOLD 2, n=28 GOLD 3, n=7
GOLD 4). None of the remaining patients received long-term
oxygen therapy (LTOT). All measurements were part of routine
baseline assessment for pulmonary rehabilitation [11]. Further-
more, 24 healthy elderly subjects were recruited. Healthy
volunteers were recruited amongst healthy subjects who partici-
pated in previous trials [14]. None of the healthy subjects used
physician-prescribed drugs. The study complied with the Decla-
ration of Helsinki and was approved by the local university’s ethics
committee (NL30763.068.09). Informed consent was provided by
all participants.
Study protocol
Participants performed two 6MWTs on consecutive days [15].
During both tests an accelerometer (Minimod, McRoberts, The
Hague, The Netherlands; size: 8.565.061.0 cm, weight: 70 g, +/
22G, 100 Hz sampling frequency) was attached to the trunk at
the level of the sacrum using an elastic belt to collect raw signalling
data. Data obtained during the 6MWT resulting in the highest
distance were used for further analyses. Prior to and immediately
after each 6MWT participants were asked to report dyspnea and
fatigue on a ten-point Borg scale. The best 6-minute walk distance
was expressed as a percentage of the predicted values [16].
Post-bronchodilator forced expiratory volume in the first second
(FEV1) and forced vital capacity (FVC) were determined using
spirometry and reference values were from Quanjer et al. [17].
Moreover, in the COPD patients residual volume (RV) and total
lung capacity (TLC) were determined using a whole-body
plethysmography to calculate the RV/TLC ratio as a measure
of air-trapping. Height and weight were assessed to obtain body
mass index (BMI, body weight in kilograms divided by squared
height in meters, kg/m
2). Patients also underwent physical
examination and medical history [18], Bio-electrical impedance
analysis was used (Bodystat 1500) to determine fat-free mass (FFM)
and disease specific equations were used to calculate fat-free mass
index (FFMI) [19].
Data Analysis
For data analyses of the accelerometer signals 5 seconds at the
beginning and end of the test were excluded to be sure that
possible group differences in walking pattern were not due to start
and/or stop of the 6MWT. Dedicated software written in
Matlab(c) was used to analyse the remaining 350 seconds of raw
acceleration data. The software included algorithms to calculate
the walking intensity, spatio-temporal aspects of gait and medio-
lateral stability. Walking intensity was calculated from the integral
of the modulus accelerometer output [20]. For this purpose,
accelerometer output was low-pass filtered with a fourth-order
Butterworth filter (20 Hz). The absolute value of the residual
signal was taken to rectify the signal. After this process, the area
under the curve over the complete measurement was calculated by
integrating the signal over a period of 350 seconds. This
integration was done separately for all three measurement
directions (i.e. frontal, horizontal and sagittal plane). The integral
of the modulus accelerometer output was then obtained by
summation of these values [20]. Onsets of support phases were
determined from forward accelerations as described by Zijlstra et
al. [21]. During the transition from single to double support (i.e.
after contra-lateral foot contact), the forward acceleration of the
lower trunk changes sign from positive to negative. The peak
forward acceleration preceding the change of sign coincides with
the instant of foot contact. The acceleration peak preceding a
change of sign (from positive to negative) was taken as the instant
of a left or right foot contact. Consequently the strides (=2 steps)
were identified. The cadence (strides/min) was calculated from the
mean stride times. The inter-stride trunk acceleration variability
Figure 1. Directions of displacement. AP: Anterior-posterior
direction (forward-backward displacement), V: Vertical direction (up-
down displacement), ML: medio-lateral direction (left-right displace-
ment)
doi:10.1371/journal.pone.0037329.g001
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procedure [22], which previously has been used to identify
walking patterns of frail and fatigued elderly [5,22]. The
autocorrelation function estimates how a time series is correlated
with itself over different time lags. For a time series of trunk
accelerations during walking, autocorrelation coefficients can thus
be produced to quantify the peak values at the first and second
dominant period, representing phase shifts equal to one step and
one stride, respectively. Variability, as measured by the autocor-
relation coefficients were calculated for the anterior-posterior,
vertical and medio-lateral direction [23]. A higher autocorrelation
coefficient indicates lower between-stride time variability (range: 0
to 100%).
Sample Size and Power
Sample size and power sample size calculations are based on
outcomes of Moe-Nilsson et al. using the interstride trunk
acceleration variability of fit and frail older adults [22]. Twenty-
two participants in each group would provide 80% power at alpha
0.05 (two-tailed) to detect differences between COPD patients and
healthy subject of 8% with a standard deviation of 10%. To cover
a larger spectrum of COPD severity by having enough patients in
disease stages 1/2 and 3/4, 93 COPD patients enrolled the study.
Statistical Analysis
Statistical analysis was done using SPSS software (version 15.0,
SPSS Inc.). Data are reported as mean 6 standard deviation (SD)
or percentages, as appropriate. GOLD stages 1 and 2, and GOLD
stages 3 and 4 were combined for further analyses due to the small
number of GOLD stage 1 (n=8) and GOLD stage 4 patients
(n=7). The comparisons were conducted with 1-way analysis of
variance or chi-square tests as appropriate. Accelerometer features
(walking intensity, cadence, variability in anterior-posterior,
vertical and medio-lateral direction), subject characteristics (gen-
der, age, height, weight and FEV1) and perceived dyspnea and
fatigue (before and after the best 6MWT) were tested in their
association with the 6MWD via multiple ordinary least squares
(OLS) regression models per group. Previously, different patterns
were found for the variability in medio-lateral direction versus
anterior-posterior and vertical directions between frail or fatigued
persons and fit persons [5,22]. Therefore the interactions between
variability for the different directions were also tested. Multi-
collinearity tests were carried out variables were retained in the
model if the variance inflation factor was smaller than 5.0. A top-
down procedure was handled for the selection of the final model
variables. Accelerometer features probably rely, at least in part, on
the walking speed. Therefore, a posteriori walking variability
measures were compared in a subset of healthy subjects and
COPD patients who had on average a comparable walking
distance (range 6MWD: 560 m–640 m). Differences in walking
patterns between the best and worst 6MWT in patients with
COPD are described in the Text S1, table S1 and table S2. A priori,
results were considered statistically significant when p-value was
#0.05.
Results
Characteristics
Healthy subjects and COPD patients had a similar gender
distribution, age and BMI (table 1). As expected, GOLD stage 3/4
patients had the worst 6MWD, also after correction for
confounding variables, like height, weight, age and gender [16].
COPD patients experienced more fatigue and dyspnea during the
6MWT compared to healthy elderly subjects.
Accelerometer features
Accelerometer features showed that COPD patients walked at a
significantly lower intensity and a lower cadence (table 2).
Differences in intensity and cadence were also found between
patients in GOLD stages 3/4 and GOLD stages 1/2. Moreover
significantly increased variability (as measured by the lower
autocorrelation coefficients) was found for the medio-lateral
acceleration in the COPD group compared to healthy controls.
A posteriori analysis
Healthy subjects (n=8) and COPD patients (n=14) with a
6MWD range between 560 m and 640 m did not differ
significantly in 6MWD (healthy: 595613 m, COPD:
596620 m, p=0.869), walking intensity (healthy:1178261083
a.u., COPD: 1150162013 a.u., p=0.720) and cadence (healthy:
6463 strides/min, COPD: 6164 strides/min, p=0.107). Never-
theless, the COPD patients maintained to have a significantly
lower autocorrelation coefficient in the medio-lateral direction
compared to the healthy control subjects (healthy: 8167%,
COPD: 67612%, p=0.003).
Determinants of 6MWD
The intensity parameter walking intensity correlated most
strongly with the 6MWD in healthy subjects (r=0.902,
p,0.001) and COPD patients (r=0.872, p,0.001) (figure 2).
The correlation between 6MWD and FEV1 in COPD (r=0.452,
p,0.001) and between walking intensity and FEV1 in COPD
(r=0.495, p,0.001) were both significant. No significant corre-
lations between these variables were found in healthy subjects.
Table 1. Patients’ characteristics.
Healthy All COPD GOLD 1/2 GOLD 3/4
(n=24) (n=79) (n=44) (n=35)
Men (%) 62.5 59.5 59.1 60.0
Age (yrs) 63.7 (5.9) 64.3 (8.9) 64.9 (8.5) 63.5 (9.5)
Height (m) 1.73 (0.07) 1.67 (0.09)* 1.67 (0.10)* 1.66 (0.06)*
Weight (kg) 79.5 (13.2) 69.0 (15.0)* 70.1 (16.3)* 67.5 (13.2)*
BMI (kg/m
2) 25.8 (3.8) 24.7 (4.5) 25.0 (4.6) 24.3 (4.3)
Tiffeneau index (%) 77.0 (4.1) 40.7 (11.9)* 47.6 (9.3)* 31.9 (8.4)*
#
FEV1 (%pred) 124.9 (21.0) 53.5 (18.7)* 66.6 (14.0)* 37.0 (7.2)*
#
RV/TLC ratio (%) - 50.5 (10.0) 45.6 (8.9) 56.8 (7.5)
#
6MWD (m) 672 (85) 494 (96)* 528 (95)* 451 (79)*
#
6MWD (% pred) 102.3 (11.6) 77.6 (13.5)* 83.4 (12.0)* 70.3 (11.7)*
#
Baseline dyspnea
(points)
0.31 (0.51) 1.64 (1.22)* 1.34 (1.19)* 2.01 (1.18)*
#
D Dyspnea (points) 1.33 (1.33) 2.74 (1.97)* 2.77 (2.04)* 2.70 (1.91)*
Baseline fatigue
(points)
0.50 (0.81) 1. 52 (1.48)* 1.41 (1.53)* 1.66 (1.42)*
D Fatigue (points) 1.13 (1.27) 2.25 (1.76)* 2.22 (1.52)* 2.30 (2.04)*
FFM (kg) - 46.5 (8.8) 47.3 (9.1) 45.6 (8.5)
FFMi (kg/m
2) - 16.6 (2.2) 16.8 (2.1) 16.3 (2.3)
Value expressed as mean 6 standard deviation (SD).
Abbreviations: BMI: body mass index, FEV1: forced expiratory volume in the first
second, RV: residual volume,TLC: total lung capacity, 6MWD: 6-min walk
distance, FFM: fat-free mass, FFMi: fat-free mass index.
*: significantly different from healthy subjects. (p,0.05).
#: significantly different from GOLD stage 1/2. (p,0.05).
doi:10.1371/journal.pone.0037329.t001
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associations between subject characteristics, accelerometer features
and 6MWD for healthy subjects and COPD patients (all GOLD
stages) are summarised in table 3. The model variables explained
85% and 88% of the variability in 6MWD in healthy subjects and
COPD patients, respectively. walking intensity and height were
the only two significant determinants of 6MWD in healthy elderly
subjects. In patients with COPD also age, cadence, walking
variability measures and their interactions were included.
Discussion
The present study provides the first comprehensive evaluation
of qualitative and quantitative measures of the walking pattern
during 6MWT in patients with moderate to very severe COPD. It
extends previous work on the 6MWT by providing detailed
information on walking variability. On average, COPD patients
walk with a lower intensity, a lower cadence and show a higher
medio-lateral variability during 6MWT in comparison with
healthy elderly subjects. The difference in medio-lateral variability
remained even if the walking speed was similar. Moreover,
walking variability was associated with functional exercise capacity
in COPD patients, but not in healthy controls. These results
indicate an altered walking pattern in COPD patients.
Increased variability in the medio-lateral direction (largely due
to through lateral foot placement) is an active control strategy to
compensate for balance disturbances in order to maintain stability
in the anterior-posterior direction (the direction of propulsion). In
the present study, walking variability was higher in the medio-
lateral direction in COPD patients compared to the control group
(table 2), suggesting larger balance disturbances during the 6MWT
in the patients. This may at least in part contribute to the relatively
high energetic costs of a 6MWT in patients with COPD [24].
Moreover, this may also explain partially why patients with COPD
experience abnormalities with day-to-day walking [25], including
falls [26]. Indeed similar deviations in walking patterns were
previous observed in frail elderly who fell at least once during the
last year or who used walking aid [22].
A high positive association was found between the intensity
parameter walking intensity and 6MWD in both COPD patients
and healthy controls (figure 2). Previously, similar findings were
reported in patients with chronic heart failure [10], [27]. These
high associations create future possibilities for routine assessment
of exercise performance of patients in a home-based setting in the
context of telemedicine. Moreover, multiple accelerometer
features and subject characteristics explained 88% of the
variability in 6MWD in the patients with COPD. Next to familiar
determinants of the 6MWD in COPD (i.e., height and age), also a
higher walking intensity, a higher cadence, lower variability in
anterior-posterior and vertical directions, and a higher variability
in medio-lateral direction were significantly associated with a
higher 6MWD (table 3). Moreover, interactions between variabil-
ity in anterior-posterior and vertical direction and between vertical
en medio-lateral direction were found. The degree of airflow
limitation (e.g., FEV1) did not significantly explain the variance in
6MWD in a multiple model.
Previously, the cadence and the walking intensity have been
studied in patients’ home-environments to evaluate daily perfor-
mance in COPD patients or to study the effects of pulmonary
rehabilitation [28]. The present study shows that walking
variability is also a clinically relevant variable in COPD patients
as it significantly contributes to the prediction of 6MWD. This is
an important finding as lower 6MWD has been related to more
Table 2. Accelerometer features.
Healthy COPD GOLD 1/2 GOLD 3/4
(n=24) (n=79) (n=44) (n=35)
Walking intensity (counts/min) 14054 (3198) 8658 (2971)* 9892 (3214)* 7106 (1654)*
#
Cadence (strides/min) 66 (4) 57 (6)* 59 (5)* 55 (5)*
#
AC-AP (%) 81.9 (10.4) 79.0 (10.7) 79.4 (9.7) 78.5 (12.0)
AC-V (%) 87.3 (6.9) 84.2 (10.2) 85.6 (6.8) 82.5 (13.3)
AC-ML (%) 73.7 (12.5) 63.2 (14.0)* 64.4 (12.4)* 61.6 (15.9)*
Value expressed as mean 6 standard deviation (SD).
Abbreviations: AC-AP: autocorrelation coefficient in anterior-posterior direction, AC-V: autocorrelation coefficient in vertical direction, AC-ML: autocorrelation coefficient
in medio-lateral direction.
*: significantly different from healthy subjects. (p,0.05).
#: significantly different compared to GOLD 1/2. (p,0.05).
doi:10.1371/journal.pone.0037329.t002
Figure 2. Relation between the accelerometer output walking
intensity per min and the 6MWD. A: GOLD stages 1 and 2 with
open squares and GOLD stages 3 and 4 with closed circles and B:
Healthy subjects
doi:10.1371/journal.pone.0037329.g002
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patients with COPD [2].
The design of this study was cross-sectional. Future investiga-
tions using the current methodology should include repeated
measures to investigate the effect of a comprehensive pulmonary
rehabilitation program on walking pattern in patients with COPD.
Indeed, faster walking may be more stable than slow walking [29].
On the other hand, this study showed that also the COPD patients
with the same walking speed as healthy subjects have an increased
variability in the medio-lateral direction. This strongly suggests
that the differences found in walking variability between COPD
and healthy cannot be attributed only to differences in walking
speed. It is therefore more likely that in COPD patients walking
stability is influenced by dyspnea [30], altered breathing dynamics
[31], reduced arm swing, [32], lower muscle strength and/or
coordination [5,6], disturbed balance [7,33], or a combination
thereof. Accelerometers may be helpful to evaluate 6-min walking
patterns as an index of treatment outcome. Moreover current
findings should be reproduced in the patients own environment.
Participants who stopped during both 6MWT were excluded
from this study, which was necessary to obtain reliable measures of
walking variability [13]. As a result, the 6MWD of the COPD
patients was higher compared to previous studies [15,34]. Then
again, the current mean 6MWD of 494 m is well within the range
in 6WMD as observed in the ECLIPSE study [3]. The Modified
Medical Research Council (MMRC) Dyspnea Scale was not
assessed, therefore it cannot be excluded that dyspnea may have
contributed to the 6MWD in patients with COPD [3]. The
present results are hypothesis-generating rather than definitive.
Future studies are warranted to corroborate the present findings
and to explain why patients with COPD have a different walking
pattern compared to healthy elderly subjects. This may be due to a
variety of factors [5,6,7]. Moreover, the current findings generate
a clear rationale to study in detail walking patterns using tri-
dimensional analyses, including electromyographic activity of
lower-limb muscles [35].
In conclusion, patients with COPD have a different walking
pattern during 6MWT compared to healthy elderly subjects, as
objectified by using accelerometer signals. In addition to walking
intensity, cadence and walking variability are important variables
associated with 6MWD in patients with COPD. These differences
in walking pattern partially explain the reduction in 6MWD in
patients with COPD.
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Table 3. Model variables influencing the 6MWD – Linear Regression.
Healthy COPD
(n=24) (n=79)
Height (m) 242.6 [54.4–430.3] 244.8 [132.4–357.2]
Age (y) NS 21.03 [22.02–20.04]
Walking intensity (counts/min) 0.023 [0.018–0.028] 0.019 [0.016–0.023]
Cadence (strides/min) NS 3.01 [0.81–5.20]
AC-AP (%) NS 15.15 [5.30–24.99]
AC-V (%) NS 10.19 [4.28–16.11]
AC-ML (%) NS 210.84 [217.09–24.60]
AC-AP*AC-V (interaction) NS 20.18 [20.30–20.06]
AC-V*AC-ML (interaction) NS 0.12 [0.05–0.19]
Model Constant 270.82 [2391.68–250.04] 2991.1 [21491.9–2490.26]
Adjusted Model R
2 0.85 0.88
Value expressed as Beta’s (ß) 695% confidence interval [CI].
Abbreviations: AC-AP: autocorrelation coefficient in anterior-posterior direction, AC-V: autocorrelation coefficient in vertical direction, AC-ML: autocorrelation coefficient
in medio-lateral direction.
Note: effects of the following variables were also tested, but no statistical significance was detected: Gender, weight, FEV1, perceived dyspnea and fatigue (before –
after the 6MWT), interaction between the autocorrelation coefficient in anterior-posterior and medio-lateral direction.
doi:10.1371/journal.pone.0037329.t003
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